Nyendo
JF-Expert Member
- Jun 4, 2017
- 1,194
- 4,115
Vizuizi vingi vilivyosalia vinaonekana kuwa vya kisheria, kulingana na Vasily Lazarev wa Wakala wa Tiba na Biolojia ya Kimedikali ya Urusi.
Watafiti wa matibabu wa Urusi wanaweza kuwa na uwezo wa kutumia chanjo za kansa ndani ya miaka michache ijayo, ikizingatiwa ufadhili wa kutosha na msaada kutoka kwa wabunge, afisa wa ngazi ya juu katika Wakala wa Tiba na Biolojia ya Kimedikali (FMBA) alisema Alhamisi.
Maoni haya yanakuja baada ya Rais Vladimir Putin kusema mwezi uliopita kwamba nchi hiyo ilikuwa "hatua moja tu" kutoka kwa kuendeleza chanjo dhidi ya kansa.
"Ikiwa msaada wa kifedha utatolewa, naamini kwamba katika miaka miwili au mitatu mashirika yaliyopo yataweza kutekeleza chanjo za kansa," Vasily Lazarev, naibu mkurugenzi wa Kituo cha Kitaifa cha Sayansi na Tiba cha Lopukhin kwa Tiba ya Kikemia na Kimwili, aliiambia RTVI.
Wawekezaji wa kibinafsi wa ndani pia watavutwa na teknolojia "baada ya shinikizo la kisheria kupungua," aliongeza.
Lazarev hakuleta changamoto yoyote ya matibabu au kiteknolojia, badala yake akichagua kuzingatia vizuizi vya kisheria vinavyokabili maendeleo ya chanjo.
"Sijui kwa haraka sheria itajengeka, inaweza kuchukua mwaka kusuluhisha masuala yote ya kisheria," alisema. "Tuna zana, miundombinu ya uzalishaji, nadhani si ngumu kuandaa."
Marekebisho yaliyopendekezwa na FMBA, ambayo itaruhusu uzalishaji na matumizi ya dawa za "muundo wa kubadilika," yataanza kufanya kazi mwezi Septemba. Pia inahitaji dawa hizo kuzalishwa katika taasisi ile ile ambayo inashikilia leseni, hata hivyo.
=======
Most remaining obstacles appear to be regulatory, according to Vasily Lazarev of Russia’s Federal Medical-Biological Agency
Russian medical researchers could be able to roll out oncological vaccines within the next couple of years, given adequate funding and support from lawmakers, a high-ranking official at the Federal Medical-Biological Agency (FMBA) said on Thursday.
The comments come after President Vladimir Putin said last month that the country was “one step away” from developing vaccines against cancer.
“If financial support is provided, I think that in two or three years existing organizations will be able to put oncology vaccines into practice,” Vasily Lazarev, deputy director of the Lopukhin Federal Scientific and Clinical Center for Physical and Chemical Medicine, told the outlet RTVI.
Domestic private investors will also be attracted to the technology “after regulatory pressure eases,” he added.
Lazarev did not bring up any medical or technological challenges, choosing instead to highlight the legal constraints facing vaccine development.
“I don’t know how quickly by-laws will be developed, it could take a year to resolve all the regulatory issues,” he said. “We have the tools, the production facilities, I think it’s not difficult to organize.”
Amendments proposed by the FMBA, which would allow for the production and use of “variable composition” medication, will go into effect in September. They also require the drugs to be produced at the same institution that holds the patent, however.
“Organizing such production at home will be quite expensive, although it is feasible,” Lazarev said. “Most likely, these will be regional centers and maybe specialized oncological institutions.”
There are currently only a handful of facilities that could handle the production requirements, such as the Blokhin Cancer Center or the FMBA’s Federal Center for Brain and Neurotechnology, both located in Moscow.
Variable-composition neoantigens, which vaccine developers have focused on, don’t quite fit the current Russian legal framework and could not be used in treatments at all until very recently.
Putin revealed the development of cancer vaccines at the Future Technologies Forum in Moscow last month. The Russian president mentioned them among the developing medical technologies that he described as approaching science fiction.
Pia soma: Putin: Urusi iko Karibu kuzindua Chanjo ya Saratani
Watafiti wa matibabu wa Urusi wanaweza kuwa na uwezo wa kutumia chanjo za kansa ndani ya miaka michache ijayo, ikizingatiwa ufadhili wa kutosha na msaada kutoka kwa wabunge, afisa wa ngazi ya juu katika Wakala wa Tiba na Biolojia ya Kimedikali (FMBA) alisema Alhamisi.
Maoni haya yanakuja baada ya Rais Vladimir Putin kusema mwezi uliopita kwamba nchi hiyo ilikuwa "hatua moja tu" kutoka kwa kuendeleza chanjo dhidi ya kansa.
"Ikiwa msaada wa kifedha utatolewa, naamini kwamba katika miaka miwili au mitatu mashirika yaliyopo yataweza kutekeleza chanjo za kansa," Vasily Lazarev, naibu mkurugenzi wa Kituo cha Kitaifa cha Sayansi na Tiba cha Lopukhin kwa Tiba ya Kikemia na Kimwili, aliiambia RTVI.
Wawekezaji wa kibinafsi wa ndani pia watavutwa na teknolojia "baada ya shinikizo la kisheria kupungua," aliongeza.
Lazarev hakuleta changamoto yoyote ya matibabu au kiteknolojia, badala yake akichagua kuzingatia vizuizi vya kisheria vinavyokabili maendeleo ya chanjo.
"Sijui kwa haraka sheria itajengeka, inaweza kuchukua mwaka kusuluhisha masuala yote ya kisheria," alisema. "Tuna zana, miundombinu ya uzalishaji, nadhani si ngumu kuandaa."
Marekebisho yaliyopendekezwa na FMBA, ambayo itaruhusu uzalishaji na matumizi ya dawa za "muundo wa kubadilika," yataanza kufanya kazi mwezi Septemba. Pia inahitaji dawa hizo kuzalishwa katika taasisi ile ile ambayo inashikilia leseni, hata hivyo.
=======
Most remaining obstacles appear to be regulatory, according to Vasily Lazarev of Russia’s Federal Medical-Biological Agency
Russian medical researchers could be able to roll out oncological vaccines within the next couple of years, given adequate funding and support from lawmakers, a high-ranking official at the Federal Medical-Biological Agency (FMBA) said on Thursday.
The comments come after President Vladimir Putin said last month that the country was “one step away” from developing vaccines against cancer.
“If financial support is provided, I think that in two or three years existing organizations will be able to put oncology vaccines into practice,” Vasily Lazarev, deputy director of the Lopukhin Federal Scientific and Clinical Center for Physical and Chemical Medicine, told the outlet RTVI.
Domestic private investors will also be attracted to the technology “after regulatory pressure eases,” he added.
Lazarev did not bring up any medical or technological challenges, choosing instead to highlight the legal constraints facing vaccine development.
“I don’t know how quickly by-laws will be developed, it could take a year to resolve all the regulatory issues,” he said. “We have the tools, the production facilities, I think it’s not difficult to organize.”
Amendments proposed by the FMBA, which would allow for the production and use of “variable composition” medication, will go into effect in September. They also require the drugs to be produced at the same institution that holds the patent, however.
“Organizing such production at home will be quite expensive, although it is feasible,” Lazarev said. “Most likely, these will be regional centers and maybe specialized oncological institutions.”
There are currently only a handful of facilities that could handle the production requirements, such as the Blokhin Cancer Center or the FMBA’s Federal Center for Brain and Neurotechnology, both located in Moscow.
Variable-composition neoantigens, which vaccine developers have focused on, don’t quite fit the current Russian legal framework and could not be used in treatments at all until very recently.
Putin revealed the development of cancer vaccines at the Future Technologies Forum in Moscow last month. The Russian president mentioned them among the developing medical technologies that he described as approaching science fiction.
Pia soma: Putin: Urusi iko Karibu kuzindua Chanjo ya Saratani
